Abstract: A structurally enhanced tissue graft has at least one placental membrane having a corrugated portion made of a series of pleated peaks and valleys. The structurally enhanced tissue graft further may have one or both of a first and second flat portion tissue membrane adhered to the corrugated portion. The first flat portion is adhered to an external surface along either peaks or valleys of the corrugated portion. The second flat portion tissue membrane adhered to the corrugated external surface along the corrugated portion opposing peaks or valleys. The first flat portion forms a top or bottom of the structurally enhanced tissue graft and the second flat portion forms an opposing bottom or top with the corrugated portion sandwiched therebetween.

Abstract: A transplant product derived from human umbilical cord has a collagenous tissue membrane derived from an umbilical cord, configured as a soft tissue barrier or wound covering or other internal or external wound healing attachment. The structural, chemical and biochemical properties are retained, the collagenous tissue membrane is cleaned removing the veins, arteries and Wharton's jelly without exposure to harsh chemicals. The collagenous tissue membrane is soaked in normal saline solution under mild agitation for a predetermined time to structurally increase tear resistance of the membrane. The collagenous tissue membrane is free of meconium. The collagenous tissue membrane has a general transparent or translucent appearance of a clear or slightly pink color. In one embodiment, the transplant product has one or more suture entry sites to facilitate suturing the product to tissue.

Abstract: A transplant product made from human amniotic fluid has a supernatant from filtered and centrifuged amniotic fluid, the amniotic fluid when recovered aseptically having a clear, translucent to slightly pink or tan color. The supernatant had been taken from the amniotic fluid which had been passed through a 170 to 260 micron blood filter, then centrifuged for 5 minutes or more at 400 g and thereafter the supernatant was separated from a pellet of debris, leaving the biochemical properties intact, wherein the supernatant is cryofrozen in sized cryovials having 0.25 to 2.0 ml of the supernatant at a temperature of ?65 degrees or less prior to use and the transplant products method of use. The transplant product contains cellular material, cell fragments, proteins and growth factors maintaining the biochemical properties and is non-immunogenic while having particles up to 170 microns being passable through a 30 gauge syringe for injection.

Abstract: A particulate composition for stimulating nucleus pulposus regeneration has a particulate composition made of vertebral end-plates having an osseous component wherein the composition is milled, ground or particulized into particles from 10 to 1000 microns in size. At least a part of the composition can be non-demineralized or demineralized or a mixture of demineralized and non-demineralized particles from the vertebral end-plates. Preferably, the non-demineralized part is not subjected to harsh chemical treating. To possibly enhance the release of growth factors and other similar substances from the osseous layer of the end-plate, the material may be treated with hydrochloric acid, ethylene diamine or other demineralizing agents or regimens.

Abstract: A placental tissue assembly for treating wounds or surfaces of a patient has one or more layers of placental tissue and a backing material. The one or more layers of placental tissue have a first side and a second side. The backing material is adhered to and covers one of either the first or second sides of the one or more layers of placental tissue to create the assembly. The assembly when applied onto a surface to be treated on the side of the tissue opposite the backing material adheres to the surface with an attachment force greater than an attachment force of the backing material adhered to the first or second side. This allows the backing material to be released leaving the placental tissue affixed to the surface to be treated.

Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture is compatible with biologic function.

Abstract: The present invention relates to a fenestrated bone graft and a method of preparing cortical bone in thin strips then fully demineralizing it to give it formed flexibility and then creating fenestrations in the cortical bone in a fashion similar to but not identical to skin grafts.

Abstract: The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).

Abstract: The invention is a novel method of sterilizing bone and soft tissues intended for human transplantation. In one embodiment the process includes steps of subjecting transplants to high hydrostatic pressures of aqueous fluid to which chlorhexidine gluconate or similar sterilizing chemicals have been added.

Abstract: A dynamic biometric mesh (10) has a plurality of radial members (30) and a plurality of catenaries (20). Each catenary (20) extends between and is fixed to at least one pair of adjacent radial members (30). The plurality of catenaries (20) and radial members (30) form a low mass structural system arranged in an architecture configured to be structurally stable in tension and pliable for deployment and integration with biologic tissue.

Abstract: A method for production of large numbers of cartilage cells with phenotype retention intended for treatment of articular cartilage lesions or preparing viable cartilage tissue by propagation of chondrocytes from cartilage explants, human or animal, with the retention of phenotypes of the cartilage cells, in which cells are chondrocytes retaining morphologic attributes of the same or chondrocyte progenitor cells. The method includes culturing the cells in which cultured cells are organized into mature hyaline cartilage on the surface of biologic structures such as cancellous or cortical bone lamina. The method for culturing chondrocytes to produce three dimensional cellular structures consisting of cartilage cells and cell produced extracellular cartilage matrix.

Abstract: A spinal implant device has a synthetic or metallic or a combination thereof of these materials in an implant body structure and stem cells in a coating, or a sheet, wrap or a membrane wrap applied to surfaces on the implant body structure or alternatively filled with a plug of stem cell laden material. The implant body structure preferably has an aperture or channel. The spinal implant device may include anchoring holes to secure the device to the spinal skeletal structure with fasteners or alternatively can simply be held in place by and between adjacent vertebrae.

Abstract: Particulate bone and structural bone, more specifically decalcified bone from endosteum having osteoinductive capacity and methods for their isolation and production are provided, more specifically, decalcified bone preparations derived from endosteal layer of bone are provided. Compositions formulated with material from endosteal layer of bone are provided along with preparation and methods of using decalcified endosteal compositions are disclosed. Endosteum is avascular and areolar in distinction to bone marrow which fills the canal. Because of its structure and anatomic position, endosteum is difficult to isolate and recognize, and therefore not regarded as an important constituent of allograft materials. One embodiment of the present invention allows for recognition and isolation of endosteum.

Abstract: Particulate bone and structural bone, more specifically decalcified bone from endosteum having osteoinductive capacity and methods for their isolation and production are provided, more specifically, decalcified bone preparations derived from endosteal layer of bone are provided. Compositions formulated with material from endosteal layer of bone are provided along with preparation and methods of using decalcified endosteal compositions are disclosed. Endosteum is avascular and areolar in distinction to bone marrow which fills the canal. Because of its structure and anatomic position, endosteum is difficult to isolate and recognize, and therefore not regarded as an important constituent of allograft materials. One embodiment of the present invention allows for recognition and isolation of endosteum.

Abstract: An improved bone screw for humans or mammals is a bone screw having exposed surfaces along a shank and threads extending from the shank with one or more selected portions of the exposed surfaces having a 3-dimensional pattern. The pattern provides enhanced resistance to thread loosening when affixed to bone. The exposed surface is on exterior portions of the threads or portions of the shank or both. The one or more selected portions of the exposed portions having a bone formation enhancing 3-dimensional patterns are in the external exposed thread surfaces or in the exposed shank surfaces or both.

Abstract: A composition of a bone repair mixture has a quantity of allograft particulate bone having a bone particle distribution of particle sizes less than 700 micron and a quantity of biologic carrier material intermixed with the particulate bone. The biologic carrier material is one of fascia, deep fascia or a fascia mixture. Preferably, the carrier material is exclusively fascia lata.

Abstract: The present invention is a composition of a self-assembly of collagen fibers made from a plurality of sized pieces of a source material. The source material made from animal or human tissue selected from one of dermis, tendon, fascia or dura mater. The self-assembly occurring by induction of a magnetic field in a liquid medium.

Abstract: A composition of a bone repair mixture has a quantity of allograft particulate bone having a bone particle distribution of particle sizes less than 700 micron and a quantity of biologic carrier material intermixed with the particulate bone. The biologic carrier material is one of fascia, deep fascia or a fascia mixture. Preferably, the carrier material is exclusively fascia lata.

Abstract: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.

Abstract: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.